Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on April 1, 2019. The filing serves to announce the company's financial results for the fourth quarter and the full fiscal year ended December 31, 2018. The registrant is incorporated in California and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.02 states that the detailed financial results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this document.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this filing. The document acts solely as a notification that the results for the period ended December 31, 2018, have been issued.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer. It warns that statements containing words such as "may," "will," "believes," or "expects" are not historical facts and that actual results may differ materially due to various factors. The registrant directs investors to the "Risk Factors" section of its Form 10 for additional details on potential risks. The company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated April 1, 2019), as they are not listed in this summary text.
- Confirm the company name is OncoCyte Corporation, as the input metadata referenced "Insight Molecular Diagnostics Inc." which does not match the registrant in the filing.
- Review the "Risk Factors" in the company's Form 10 to understand the contingencies affecting the forward-looking statements.
- Note that the information in Item 2.02 is deemed "furnished" and not "filed" under Section 18 of the Exchange Act, limiting liability for that specific content.